News

The LIBERTY study will evaluate the effects of ubenimex added to current standard of care in patients with pulmonary arterial hypertension (PAH). Despite multiple approved vasodilator therapies, PAH

This approval will initiate the first store brand launch of an equivalent product to Zegerid OTC capsules. This product will be packaged and marketed as a store brand or

The high demand for site-specific labeling technologies and potential for deal-making in the field of antibody-drug conjugates (ADC) that has emerged during APC's recent business development activities, particularly

The Company intends to use the net proceeds from this capital increase as follows:      • To initiate and progress the Phase 3 Imeglimin program in Japan

The projected FDA’s action date is 11 November, while the EMA's centralized review process is underway. The data supporting both applications were generated in the phase 3 Checkmate-141

The objectives of the trial are to demonstrate: 1. IntelGenx oral film product will provide therapeutically effective blood levels of montelukast, and; 2. montelukast when delivered using IntelGenx

The randomized, double-blind, placebo-controlled study will enroll approximately 70 healthy volunteers to evaluate the safety and tolerability of NYX-2925 at multiple doses. The study will include both single-dose

The deal includes several biosimilars in late-stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will remain responsible for the development

Developed in the lab of Professor Edward Schuchman, PhD, at the Icahn School of Medicine at Mount Sinai, rhAC showed promising results in a mouse model of Farber